Molecular typing is predicated on molecular genetic testing and isn't however routinely available. Molecular subtypes and immunohistochemical surrogate markers on the tumors (HR, HER2, triple damaging) correlate in about 70%. The differentiation of luminal A and B subtypes by HR standing and proliferation markers like Ki-67 may be beneficial, https://scottl308ckq4.blogthisbiz.com/profile